Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 11/20 | 0.48 |
| ▸ | BMPR1A | P36894 | 5/20 | 0.48 |
| ▸ | BMPR1B | O00238 | 3/20 | 0.48 |
| ▸ | ACVR1B | P36896 | 3/20 | 0.48 |
| ▸ | ACVRL1 | P37023 | 3/20 | 0.48 |
| ▸ | KDR | P35968 | 5/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAK | O14976 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24409706 | 0.95 | ACVR1 (0.53) | ACVR1BMPR1ABMPR1BACVR1BACVRL1 | |
| SCHEMBL24409629 | 0.90 | ACVR1 (0.59) | ACVR1BMPR1ABMPR1BACVR1BACVRL1 | |
| SCHEMBL24409645 | 0.84 | ACVR1 (0.44) | ACVR1BMPR1ABMPR1BACVR1BACVRL1 | |
| SCHEMBL17442280 | 0.83 | ACVR1 (0.47) | ACVR1BMPR1ABMPR1BACVR1BACVRL1 | |
| SCHEMBL17441883 | 0.83 | ACVR1 (0.58) | ACVR1BMPR1ABMPR1BACVR1BACVRL1 | |
| SCHEMBL24409703 | 0.80 | ACVR1 (0.46) | ACVR1BMPR1ABMPR1BACVR1BACVRL1 | |
| SCHEMBL24409601 | 0.80 | ACVR1 (0.57) | ACVR1BMPR1ABMPR1BACVR1BACVRL1 | |
| SCHEMBL24409611 | 0.79 | ACVR1 (0.48) | ACVR1BMPR1ABMPR1BACVR1BACVRL1 | |
| SCHEMBL17441658 | 0.79 | ACVR1 (0.59) | ACVR1BMPR1ABMPR1BACVR1BACVRL1 | |
| SCHEMBL17442202 | 0.79 | ACVR1 (0.52) | ACVR1BMPR1ABMPR1BACVR1BACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023081212-A1 | METHODS OF USING ALK2 INHIBITORS | KEROS THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2022099166-A1 | METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE | KEROS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022098821-A1 | METHODS OF TREATING LYMPHOPENIA | KEROS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022098812-A1 | METHODS OF TREATING IRON OVERLOAD | KEROS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |